American Journal of Cancer

, Volume 1, Issue 3, pp 223–235 | Cite as

Opinion and Evidence in Cancer

From the World Literature


Section 1

  1. Savage DG, Antman KH. Imatinib mesylate — a new oral targeted therapy. N Engl J Med 2002; 346: 683–93PubMedCrossRefGoogle Scholar

Section 2

  1. Schuler M. p53 gene therapy: clinical experience to date. Am J Cancer 2002; 1(1): 3–6CrossRefGoogle Scholar

Section 3

  1. 1.
    D’Incalci M. Editorial comment. Eur J Cancer 2002; 38: 17PubMedCrossRefGoogle Scholar
  2. 2.
    Vignati S, Codegoni A, Polato F, et al. Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer 2002; 38: 177–183PubMedCrossRefGoogle Scholar
  3. 3.
    Mizutani Y, Nakanishi H, Yoshida O, et al. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002; 38: 167–176PubMedCrossRefGoogle Scholar

Section 4

  1. Moreau P, Facon T, Attal M, et al., for the Intergroupe Francophone du Myélome. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002; 99: 731–5PubMedCrossRefGoogle Scholar

Section 5

  1. Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002; 20: 160–4PubMedCrossRefGoogle Scholar

Section 6

  1. Karnon J, Brown J, for the Adjuvant Breast Cancer (ABC) Steering Committee. A stochastic economic evaluation comparing tamoxifen plus chemotherapy with tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer. PharmacoEconomics 2002; 20(2): 119–37PubMedCrossRefGoogle Scholar

Section 7

  1. Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, et al. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2002; 84: 241–4PubMedCrossRefGoogle Scholar

Section 8

  1. Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002; 25: 72–81PubMedCrossRefGoogle Scholar

Section 9

  1. Bafaloukos D, Gogas H, Georgoulias V, et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002; 20: 420–5PubMedCrossRefGoogle Scholar

Section 10

  1. Latagliata R, Petti MC, Fenu S, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002 Feb 1; 99: 822–4PubMedCrossRefGoogle Scholar

Section 11

  1. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002 Feb 15; 20: 1000–7PubMedCrossRefGoogle Scholar

Section 12

  1. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071–8PubMedCrossRefGoogle Scholar

Section 13

  1. Greenwald P. Cancer chemoprevention. BMJ 2002; 324: 714–18PubMedCrossRefGoogle Scholar

Section 14

  1. Jia S-F, Worth LL, Turan M, et al. Eradication of osteosarcoma lung metastasis using intranasal gemcitabine. AntiCancer Drugs 2002; 13: 155–61PubMedCrossRefGoogle Scholar

Section 15

  1. Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 2002; 84: 420–5PubMedCrossRefGoogle Scholar

Section 16

  1. Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 1344–52PubMedCrossRefGoogle Scholar

Section 17

  1. Wenzel C, Locker GJ, Schmidinger M, et al. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor. AntiCancer Drugs 2002; 13: 67–74PubMedCrossRefGoogle Scholar

Section 18

  1. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer 2002; 94(4): 1166–74PubMedCrossRefGoogle Scholar

Section 19

  1. Moreno V, Bosch FX, Muñoz N, et al., for the International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359: 1085–192PubMedCrossRefGoogle Scholar

Section 20

  1. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8: 225–32PubMedCrossRefGoogle Scholar

Section 21

  1. 1.
    Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346: 1054–59PubMedCrossRefGoogle Scholar
  2. 2.
    Chau I, Cunningham D. Cyclooxygenase inhibition in cancer — a blind alley or a new therapeutic reality? N Engl J Med 2002; 346: 1085–7PubMedCrossRefGoogle Scholar

Section 22

  1. Voulgaris S, Partheni M, Karamouzis M, et al. Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol 2002; 25: 60–4PubMedCrossRefGoogle Scholar

Section 23

  1. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215–21PubMedCrossRefGoogle Scholar

Section 24

  1. Halbert RJ, Zaher C, Wade S, Malin J, Lawless GD, et al. Outpatient cancer drug costs: changes, drivers, and the future. Cancer 2002; 94(4): 1142–50PubMedCrossRefGoogle Scholar

Section 25

  1. Potosky AL, Harlan LC, Kaplan RS, et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002; 20: 1192–202PubMedCrossRefGoogle Scholar

Section 26

  1. 1.
    Roberts RO, Jacobson DJ, Girman CJ, et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002; 77: 219–25PubMedCrossRefGoogle Scholar
  2. 2.
    Barry MJ. NSAIDs and a lower risk of prostate cancer: causation or confounding? Mayo Clin Proc 2002; 77: 217–8PubMedCrossRefGoogle Scholar

Section 27

  1. 1.
    Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630–7PubMedCrossRefGoogle Scholar
  2. 2.
    Canellos GP. New treatments for advanced Hodgkin’s disease: an uphill fight beginning close to the top. J Clin Oncol 2002; 20: 607–9PubMedGoogle Scholar

Section 28

  1. 1.
    Ye Z, Hellström I, Hayden-Ledbetter M, et al. Gene therapy for cancer using singlechain Fv fragments specific for 4-1BB. Nat Med 2002; 8: 343–8PubMedCrossRefGoogle Scholar
  2. 2.
    Chen L. Antibody gene therapy: old wine in a new bottle. Nat Med 2002; 8: 333–4PubMedCrossRefGoogle Scholar

Section 29

  1. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245–7PubMedCrossRefGoogle Scholar

Section 30

  1. 1.
    Maughan TS, James RD, Kerr DJ, et al., for the British MRC Colorectal Cancer Working Party. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002; 359: 1555–63PubMedCrossRefGoogle Scholar
  2. 2.
    Bottomley A. Metastatic colorectal cancer: treatment challenges and quality of life. Lancet 2002; 359: 1537–8PubMedCrossRefGoogle Scholar

Section 31

  1. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002; 94: 1457–65PubMedCrossRefGoogle Scholar

Section 32

  1. Boisdron-Celle M, Craipeau MC, Brienza S, et al. Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemother Pharmacol 2002; 49: 235–43PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations